Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD276-Targeted CAR-T in Advanced Solid Tumors
NCT04864821Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label, single-arm trial of TAA06 in osteosarcoma (OS), neuroblastoma, gastric cancer (GC) and 1 more, sponsored by PersonGen BioTherapeutics. Primary endpoints: Adverse Events at 2 years, Objective Response Rate at 12 weeks and 1 more. Status: unknown.
02
Drugs
TAA06
03
Conditions
osteosarcoma (OS)neuroblastomagastric cancer (GC)lung cancer
Beyond the preview
Go deeper on NCT04864821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864821.